Navigation Links
Novel Vaccines Improve Potential for European Vaccines Manufacturers
Date:1/14/2009

LONDON, Jan. 14 /PRNewswire/ -- The vaccines market, which was earlier associated with low profit margins and slow growth rates, has gained momentum in recent years through innovation. The introduction of novel vaccines for diseases with high burden and continuous investments aimed at boosting production capacity is driving the growth of this previously unattractive market.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO)

New analysis from Frost & Sullivan (http://www.pharma.frost.com), European Vaccines Market, finds that the market earned revenues of $4.50 billion in 2007 and estimates this to reach $9.85 billion in 2014.

"Health authorities are prepared to spend on prevention, rather than witness expenditures on vaccine-preventable diseases spiral out of control," notes Frost & Sullivan Research Analyst John Paul. "The growing support for vaccinations from physicians and paediatricians has been fundamental to the growth of the vaccines market."

The market has shown remarkable growth in recent years as a result of the introduction of vaccines in untapped disease segments. Governments' acceptance and reimbursement of such efficient, albeit expensive, vaccines has encouraged market participants to increase investments in R&D and develop innovative and differentiated products. Innovation in technology has enabled manufacturers to move ahead into promising areas like therapeutic vaccines where the potential for growth is unlimited.

However, Europe is already at a disadvantage because of the ban on direct-to-consumer marketing. Uptake levels in Europe remain slower than in the US market. In addition to the inherent challenges in vaccine manufacture and R&D, market participants also have to deal with government policies, perceptions and awareness levels that diverge widely across Europe.

"A clear comprehension about the dynamics in various regions is important to predict demand and alter business strategies accordingly," explains Paul. "Predicting and meeting demand is one of the most challenging factors in the vaccines industry. Efficiency in manufacturing and distribution has to be achieved in order to offset limited production capacities and low profit margins."

Keeping abreast of epidemiological trends and government policies, coupled with efforts to boost physician and public awareness, will be crucial. In the context of R&D, the identification of the disease areas to be targeted, through a vaccine or a combination, is important because market penetration and revenue generation are largely dependent upon these factors in various regions.

"Vaccine manufacturers should be able to identify key market dynamics, promote efficiency of operation and support public perception while adapting and implementing lean principles and innovative marketing strategies," advises Paul. "Streamlining investments into R&D of adjuvant technologies, therapeutic and DNA vaccines could enable realisation of significant potential in these areas."

If you are interested in a virtual brochure, which provides manufacturers, end users and other industry participants with an overview of the European vaccines market, then send an e-mail to Katja Feick, Corporate Communications, at katja.feick@frost.com, with your full name, company name, title, telephone number, company e-mail address, company website, city, state and country. Upon receipt of the above information, an overview will be sent to you by e-mail.

European Vaccines Market is part of the Pharmaceuticals & Biotechnology Growth Partnership Services Programme, which also includes research in the following markets: European Therapeutic Monoclonal Antibody Markets, European Human Growth Hormones Market, European Pharma/biotech Contract Manufacturing Markets: A Strategic Outlook and European Drug Delivery Markets - Opportunity Analysis. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants. Interviews with the press are available.

Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best in class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best practice models to drive the generation, evaluation and implementation of powerful growth strategies. Frost & Sullivan leverages over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from 31 offices on six continents. To join our Growth Partnership, please visit http://frost.com.

European Vaccines Market

M276

    Contact:
    Katja Feick
    Corporate Communications
    P: +49 (0) 69 77 0 33 43
    E: katja.feick@frost.com

http://www.frost.com/


'/>"/>
SOURCE Frost & Sullivan
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. University of Ottawa Heart Institute Scientists Successfully Develop Novel Biomaterial to Help Grow New Blood Vessels
2. Merck Serono and Apitope Announce Licensing Agreement on Novel Peptide Therapeutics for the Treatment of Multiple Sclerosis
3. Frost & Sullivan Lauds Toscana Biomarkers Outstanding Contributions to the R&D of Novel Biomarkers for the Diagnosis of Autoimmune Diseases
4. BD Announces FDA 510(k) Clearance of Novel Molecular Assay to Diagnose Clostridium difficile Infections
5. Novel prostate cancer vaccine taking aim at cancer cell sweet spot
6. Onyx Pharmaceuticals Acquires Option to License Novel Highly Specific JAK2 Inhibitors From S*BIO
7. Amira Announces the Successful Completion of GLP Toxicity Studies for a Novel DP2 Antagonist.
8. Mutations common to cancer and developmental disorder examined in a novel disease model
9. Labopharm to host webcast presentation on novel trazodone formulation - tomorrow (Dec.16/08) at 10:00 a.m. ET
10. Development of Novel Assays Vital for the European Immunoassay Diagnostics Market
11. FDA Grants NeoVistas Request to Utilize Novel Wet AMD Treatment in Compassionate Case
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... 2017 , ... With less than 10,000 dermatologists in the United States and ... limited while the desire to conquer breakouts and eliminate skincare stress is widespread. ... online, today released its inaugural survey on the State of Acne in America. ...
(Date:3/28/2017)... Petersburg Florida (PRWEB) , ... March 28, 2017 , ... ... Marine Corp to raise money to for the Toys for Tots Literacy Campaign at ... federal budget in excess of $70 billion, the U.S. ranks at number 14 internationally ...
(Date:3/28/2017)... ... March 28, 2017 , ... AutismOne announced the Board Certified ... Integrative Medicine and available for application on Saturday, May 27, 2017, following Thursday, ... Colorado Springs. , Ed Arranga, president of AutismOne, stated: "Many of the modalities ...
(Date:3/28/2017)... NJ (PRWEB) , ... March 28, 2017 , ... ... Camp Association’s Tri-State Camp Conference in Atlantic City March 13-16, was a busy ... their team of professional staff discussed strategies for preventing outbreaks among camp communities ...
(Date:3/28/2017)... ... March 28, 2017 , ... Oily skin is a common and unwelcomed occurrence in ... has a lot to offer to the discussion of dealing with excess skin oil. ... there are many home remedies that can help remove the oily shine while keeping the ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... TAIPEI, Taiwan , March 28, 2017 /PRNewswire/ ... medical device company, is pleased to announce ... Series A investment of Panther Orthopedics, Inc., a ... pioneering innovative dynamic fixation solutions for orthopedic extremity ... market continues to expand rapidly, primarily due to ...
(Date:3/27/2017)... , March 27, 2017 ... better understand Eli Lilly and its partnering interests and activities ... 2010 report provides an in-depth insight into the partnering activity ... On demand company reports are prepared upon purchase to ... company data. The report will be delivered in ...
(Date:3/27/2017)... March 27, 2017  Cryoport, Inc. (NASDAQ: CYRX, CYRXW) ... to offer shares of common stock in an underwritten ... file with the Securities and Exchange Commission (the "SEC"). ... and there can be no assurance as to whether ... to the actual size or terms of the offering. ...
Breaking Medicine Technology: